Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® approved by Health Canada for both subcutaneous and intravenous ...

Kepler Capital analyst Nicolas Pauillac maintained a Buy rating on Formycon AG (FYB – Research Report) on January 7 and set a price target of ...

Regulatory ApprovalFormycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 08.01.2025 / 14:30 CET/CESTThe issuer is solely ...

FYB-206 is under development for the treatment of malignant melanoma (black skin cancer) and non-small cell lung cancer. The drug candidate is a pembrolizumab biosimilar. It acts by targeting ...

Pembrolizumab biosimilar is under clinical development by Formycon and currently in Phase III for Non-Small Cell Lung Cancer.

OtulfiTM received a Health Canada Notice of Compliance (NOC) approval on December 30th for both subcutaneous and intravenous formulationsWith this approval, Fresenius Kabi Canada's immunology ...

Approved by Health Canada for Both Subcutaneous and Intravenous Formulations to Treat Serious Inflammatory Diseases Health Canada Joins the FDA and the European Commission in Granting Regulatory ...

Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr. Die Informationen auf dem Portal BörsenNEWS.de ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Cheaper biosimilar versions of Lucentis from Samsung Bioepis/Biogen, Hospira and Formycon/Bioeq are however due to enter the US market shortly. Roche and Novartis share rights to Lucentis ...

To read the full article, click here. 3. Ahzantive Receives FDA Approval as New Eylea Biosimilar Formycon and its licensing ...